MMS22L
gene geneOn this page
Also known as dJ39B17.2
Summary
MMS22L (MMS22 like, DNA repair protein, HGNC:21475) is a protein-coding gene on chromosome 6q16.1, encoding Protein MMS22-like (Q6ZRQ5). Component of the MMS22L-TONSL complex, a complex that promotes homologous recombination-mediated repair of double-strand breaks (DSBs) at stalled or collapsed replication forks. It is a common-essential gene (DepMap: required in 99.3% of cancer cell lines).
The protein encoded by this gene forms a complex with tonsoku-like, DNA repair protein (TONSL), and this complex recognizes and repairs DNA double-strand breaks at sites of stalled or collapsed replication forks. The encoded protein also can bind with the histone-associated protein NFKBIL2 to help regulate the chromatin state at stalled replication forks. Finally, this gene appears to be overexpressed in most lung and esophageal cancers. Multiple transcript variants encoding different isoforms have been found for this gene.
Source: NCBI Gene 253714 — RefSeq curated summary.
At a glance
- GWAS associations: 35
- Clinical variants (ClinVar): 162 total
- Cancer dependency (DepMap): dependent in 99.3% of screened cell lines (common-essential)
- MANE Select transcript:
NM_001350599
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:21475 |
| Approved symbol | MMS22L |
| Name | MMS22 like, DNA repair protein |
| Location | 6q16.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | dJ39B17.2 |
| Ensembl gene | ENSG00000146263 |
| Ensembl biotype | protein_coding |
| OMIM | 615614 |
| Entrez | 253714 |
Gene structure
Transcript identifiers
Ensembl transcripts: 16 — 8 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay
ENST00000275053, ENST00000369251, ENST00000482634, ENST00000484170, ENST00000496119, ENST00000506256, ENST00000508820, ENST00000508976, ENST00000509383, ENST00000510018, ENST00000511335, ENST00000514790, ENST00000683635, ENST00000929351, ENST00000929352, ENST00000929353
RefSeq mRNA: 3 — MANE Select: NM_001350599
NM_001350599, NM_001350600, NM_198468
CCDS: CCDS5039
Canonical transcript exons
ENST00000683635 — 25 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000974785 | 97149853 | 97150020 |
| ENSE00000974786 | 97142161 | 97146887 |
| ENSE00001084130 | 97173063 | 97173222 |
| ENSE00001084131 | 97162002 | 97162165 |
| ENSE00001084132 | 97168071 | 97168240 |
| ENSE00001084133 | 97165246 | 97165457 |
| ENSE00001325412 | 97151771 | 97151867 |
| ENSE00001367907 | 97179408 | 97179559 |
| ENSE00001370802 | 97228894 | 97229403 |
| ENSE00001371519 | 97186497 | 97186690 |
| ENSE00001371771 | 97181904 | 97182054 |
| ENSE00001380242 | 97178443 | 97178585 |
| ENSE00001385237 | 97231426 | 97231652 |
| ENSE00003504632 | 97278849 | 97278898 |
| ENSE00003506261 | 97272975 | 97273062 |
| ENSE00003516513 | 97246628 | 97246690 |
| ENSE00003554438 | 97272704 | 97272881 |
| ENSE00003579047 | 97281237 | 97281362 |
| ENSE00003624103 | 97282314 | 97282553 |
| ENSE00003633202 | 97254557 | 97254733 |
| ENSE00003642259 | 97267872 | 97268002 |
| ENSE00003642304 | 97263335 | 97263448 |
| ENSE00003692017 | 97269902 | 97269992 |
| ENSE00003791095 | 97233861 | 97233980 |
| ENSE00003922136 | 97283096 | 97283216 |
Expression profiles
Bgee: expression breadth ubiquitous, 137 present calls, max score 89.41.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.3657 / max 182.1816, expressed in 1627 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 74780 | 10.3657 | 1627 |
Top tissues by expression
140 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 89.41 | gold quality |
| ventricular zone | UBERON:0003053 | 87.30 | gold quality |
| embryo | UBERON:0000922 | 84.92 | gold quality |
| ganglionic eminence | UBERON:0004023 | 84.92 | gold quality |
| bone marrow | UBERON:0002371 | 83.56 | gold quality |
| bone marrow cell | CL:0002092 | 83.44 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 83.33 | gold quality |
| corpus callosum | UBERON:0002336 | 79.31 | gold quality |
| stromal cell of endometrium | CL:0002255 | 77.90 | gold quality |
| adrenal tissue | UBERON:0018303 | 77.86 | gold quality |
| tonsil | UBERON:0002372 | 76.93 | gold quality |
| calcaneal tendon | UBERON:0003701 | 76.77 | gold quality |
| islet of Langerhans | UBERON:0000006 | 76.04 | gold quality |
| testis | UBERON:0000473 | 75.90 | gold quality |
| endometrium | UBERON:0001295 | 75.60 | gold quality |
| vermiform appendix | UBERON:0001154 | 75.28 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 75.21 | gold quality |
| lymph node | UBERON:0000029 | 74.83 | gold quality |
| monocyte | CL:0000576 | 74.55 | gold quality |
| rectum | UBERON:0001052 | 74.39 | gold quality |
| leukocyte | CL:0000738 | 74.31 | gold quality |
| right testis | UBERON:0004534 | 73.96 | gold quality |
| placenta | UBERON:0001987 | 73.80 | gold quality |
| left testis | UBERON:0004533 | 73.56 | gold quality |
| colonic epithelium | UBERON:0000397 | 73.48 | gold quality |
| cortical plate | UBERON:0005343 | 73.29 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 70.90 | gold quality |
| esophagus mucosa | UBERON:0002469 | 70.66 | gold quality |
| pancreas | UBERON:0001264 | 69.91 | gold quality |
| duodenum | UBERON:0002114 | 69.91 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-6075 | yes | 883.09 |
| E-MTAB-6678 | yes | 7.89 |
| E-ANND-3 | yes | 7.00 |
| E-GEOD-70580 | no | 168.82 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
170 targeting MMS22L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-126-5P | 100.00 | 72.71 | 3180 |
| HSA-MIR-3924 | 100.00 | 72.09 | 2394 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-5193 | 100.00 | 67.26 | 1744 |
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-1252-5P | 100.00 | 69.80 | 2774 |
| HSA-MIR-4500 | 99.99 | 72.72 | 2367 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-4789-3P | 99.99 | 70.75 | 2484 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-LET-7F-2-3P | 99.98 | 70.98 | 2588 |
| HSA-MIR-1185-1-3P | 99.98 | 71.04 | 2593 |
| HSA-MIR-1185-2-3P | 99.98 | 71.04 | 2593 |
| HSA-MIR-4789-5P | 99.98 | 70.76 | 2721 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 99.3% of screened cell lines, common-essential.
Literature-anchored findings (GeneRIF, showing 9)
- These results indicate that MMS22L and TONSL are genome caretakers that stimulate the recombination-dependent repair of stalled or collapsed replication forks. (PMID:21055983)
- MMS22L and TONSL are required for the maintenance of genome stability. (PMID:21055984)
- This study identifies MMS22L-NFKBIL2 as components of the replication stress control pathway. (PMID:21055985)
- Results strongly suggest that the Mms22L-Nfkbil2 complex contributes to genome stability by regulating the chromatin state at stalled replication forks. (PMID:21113133)
- Our data strongly suggest that targeting MMS22L as well as its interaction with NFKBIL2 could be a promising strategy for novel cancer treatments. (PMID:22895565)
- new histones incorporated during DNA replication provide a signature of post-replicative chromatin, read by the human TONSL-MMS22L homologous recombination complex (PMID:27338793)
- By specifically regulating RAD51 activity at uncoupled replication forks, MMS22L-TONSL stabilizes perturbed replication forks by promoting replication fork reversal and stimulating their homologous recombination-mediated restart in vivo. (PMID:27797818)
- uncovered DNA-PKcs-dependent DNA damage-induced ASF1A phosphorylation, which enhances chromatin assembly, promoting MMS22L-TONSL recruitment and, hence, Rad51 loading. (PMID:29478807)
- MMS22L-TONSL functions in sister chromatid cohesion in a pathway parallel to DSCC1-RFC. (PMID:36622344)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | mms22l | ENSDARG00000074691 |
| mus_musculus | Mms22l | ENSMUSG00000045751 |
| rattus_norvegicus | Mms22l | ENSRNOG00000006996 |
| drosophila_melanogaster | CG14803 | FBGN0023513 |
Protein
Protein identifiers
Protein MMS22-like — Q6ZRQ5 (reviewed: Q6ZRQ5)
Alternative names: Methyl methanesulfonate-sensitivity protein 22-like
All UniProt accessions (5): Q6ZRQ5, E2QRD4, H0Y8J1, H0YAJ2, H9KVD8
UniProt curated annotations — full annotation on UniProt →
Function. Component of the MMS22L-TONSL complex, a complex that promotes homologous recombination-mediated repair of double-strand breaks (DSBs) at stalled or collapsed replication forks. The MMS22L-TONSL complex is required to maintain genome integrity during DNA replication. It mediates the assembly of RAD51 filaments on single-stranded DNA (ssDNA): the MMS22L-TONSL complex is recruited to DSBs following histone replacement by histone chaperones and eviction of the replication protein A complex (RPA/RP-A) from DSBs. Following recruitment to DSBs, the TONSL-MMS22L complex promotes recruitment of RAD51 filaments and subsequent homologous recombination. Within the complex, MMS22L acts by binding ssDNA.
Subunit / interactions. Component of the MMS22L-TONSL complex, a complex at least composed of MMS22L and TONSL/NFKBIL2. Interacts with RAD51; interaction is direct.
Subcellular location. Nucleus. Chromosome.
Post-translational modifications. Degraded by the ubiquitin-proteasome system upon replication stress.
Similarity. Belongs to the MMS22 family. MMS22L subfamily.
RefSeq proteins (3): NP_001337528, NP_001337529, NP_940870 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR029424 | MMS22L_C | Domain |
| IPR029425 | MMS22L_N | Domain |
| IPR042320 | MMS22-like | Family |
Pfam: PF14910, PF14911
UniProt features (10 total): sequence variant 4, mutagenesis site 4, chain 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6ZRQ5-F1 | 81.77 | 0.32 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Mutagenesis-validated functional residues (4):
| Position | Phenotype |
|---|---|
| 29–32 | does not affect interaction with rad51. |
| 595–598 | does not affect interaction with rad51. |
| 1034–1037 | abolished interaction with rad51. |
| 1034 | abolished interaction with rad51. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 153 (showing top):
GOBP_DNA_TEMPLATED_DNA_REPLICATION_MAINTENANCE_OF_FIDELITY, GOCC_NUCLEAR_REPLICATION_FORK, GOBP_PROTEIN_LOCALIZATION_TO_CHROMATIN, GOBP_PROTEIN_LOCALIZATION_TO_CHROMOSOME, GOBP_DNA_DAMAGE_RESPONSE, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE, FISCHER_DREAM_TARGETS, GOBP_RECOMBINATIONAL_REPAIR, IK3_01, GOBP_DNA_REPLICATION, GOMF_SINGLE_STRANDED_DNA_BINDING, NUYTTEN_EZH2_TARGETS_DN, GOCC_MCM_COMPLEX, GAVIN_FOXP3_TARGETS_CLUSTER_P6, GOCC_TRANSCRIPTION_ELONGATION_FACTOR_COMPLEX
GO Biological Process (6): double-strand break repair via homologous recombination (GO:0000724), chromatin organization (GO:0006325), replication fork processing (GO:0031297), protein localization to chromatin (GO:0071168), DNA repair (GO:0006281), DNA damage response (GO:0006974)
GO Molecular Function (3): single-stranded DNA binding (GO:0003697), DNA binding (GO:0003677), protein binding (GO:0005515)
GO Cellular Component (9): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), site of double-strand break (GO:0035861), nuclear replication fork (GO:0043596), site of DNA damage (GO:0090734), chromosome (GO:0005694), FACT complex (GO:0035101), MCM complex (GO:0042555)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| recombinational repair | 1 |
| double-strand break repair | 1 |
| cellular component organization | 1 |
| DNA-templated DNA replication maintenance of fidelity | 1 |
| protein localization to chromosome | 1 |
| DNA metabolic process | 1 |
| DNA damage response | 1 |
| cellular response to stress | 1 |
| DNA binding | 1 |
| nucleic acid binding | 1 |
| binding | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| cytoplasm | 1 |
| site of DNA damage | 1 |
| nuclear chromosome | 1 |
| nucleus | 1 |
| replication fork | 1 |
| CMG complex | 1 |
| chromosome | 1 |
| intracellular membraneless organelle | 1 |
| chromatin | 1 |
| transcription elongation factor complex | 1 |
| protein-containing complex | 1 |
| MCM core complex | 1 |
Protein interactions and networks
STRING
1090 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| MMS22L | TONSL | Q96HA7 | 997 |
| MMS22L | ESCO2 | Q56NI9 | 658 |
| MMS22L | MCM5 | P33992 | 623 |
| MMS22L | KLHL32 | Q96NJ5 | 593 |
| MMS22L | SMARCAL1 | Q9NZC9 | 548 |
| MMS22L | MCM3 | P25205 | 523 |
| MMS22L | DDB1 | Q16531 | 515 |
| MMS22L | SFT2D2 | O95562 | 507 |
| MMS22L | RADX | Q6NSI4 | 495 |
| MMS22L | RAD51 | Q06609 | 488 |
| MMS22L | ASF1B | Q9NVP2 | 476 |
| MMS22L | MFAP3L | O75121 | 472 |
| MMS22L | GPR63 | Q9BZJ6 | 462 |
| MMS22L | MCM6 | Q14566 | 462 |
| MMS22L | ZRANB3 | Q5FWF4 | 455 |
IntAct
61 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| MCM2 | MCM4 | psi-mi:“MI:0914”(association) | 0.830 |
| H2AX | PPM1G | psi-mi:“MI:0914”(association) | 0.730 |
| H2AC4 | PPM1G | psi-mi:“MI:0914”(association) | 0.670 |
| H2BC1 | PPM1G | psi-mi:“MI:0914”(association) | 0.640 |
| ASF1B | HAT1 | psi-mi:“MI:0914”(association) | 0.640 |
| NPY2R | RTL8C | psi-mi:“MI:0914”(association) | 0.530 |
| NCR3LG1 | FAM171A2 | psi-mi:“MI:0914”(association) | 0.530 |
| MACROH2A2 | PPM1G | psi-mi:“MI:0914”(association) | 0.530 |
| SSRP1 | PARP1 | psi-mi:“MI:0914”(association) | 0.530 |
| H2BC26 | PPM1G | psi-mi:“MI:0914”(association) | 0.530 |
| H2AC18 | PPM1G | psi-mi:“MI:0914”(association) | 0.530 |
| ANKRD22 | ESYT2 | psi-mi:“MI:0914”(association) | 0.530 |
| TONSL | H2AC4 | psi-mi:“MI:0914”(association) | 0.530 |
| TONSL | MMS22L | psi-mi:“MI:0915”(physical association) | 0.500 |
| TONSL | MMS22L | psi-mi:“MI:0914”(association) | 0.500 |
| RRP1B | ZNF785 | psi-mi:“MI:0914”(association) | 0.350 |
| PACC1 | DEGS1 | psi-mi:“MI:0914”(association) | 0.350 |
| PVR | QSOX1 | psi-mi:“MI:0914”(association) | 0.350 |
| OPRM1 | EXOC5 | psi-mi:“MI:0914”(association) | 0.350 |
| H4C16 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (123): MMS22L (Affinity Capture-MS), MMS22L (Synthetic Growth Defect), MMS22L (Co-purification), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS), MMS22L (Affinity Capture-MS)
ESM2 similar proteins: A0JM49, A2AKG8, B0V0U5, B1AUR6, C5J7W8, E1BGH8, E1C231, E1C2Z0, E7FGT5, E7FH61, E9Q3L2, F6S215, O08662, O60287, O94822, P42356, P57678, P78527, P97313, Q13315, Q13535, Q14146, Q1RLU1, Q2TAW0, Q3TQQ9, Q3URQ0, Q571H0, Q5RDK1, Q5VW36, Q5WNI9, Q5XI94, Q5ZM41, Q62388, Q6A009, Q6DFV1, Q6PQD5, Q6ZRQ5, Q7SY48, Q86XI2, Q8BKX6
Diamond homologs: B1AUR6, B3DIY3, E1BGH8, E1C2Z0, Q6ZRQ5
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 64 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| RNA Polymerase I Promoter Opening | 10 | 43.9× | 8e-13 |
| DNA methylation | 10 | 42.5× | 9e-13 |
| Packaging Of Telomere Ends | 8 | 41.8× | 8e-11 |
| Defective pyroptosis | 11 | 41.0× | 1e-13 |
| SIRT1 negatively regulates rRNA expression | 10 | 40.6× | 1e-12 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 10 | 40.0× | 1e-12 |
| Inhibition of DNA recombination at telomere | 10 | 40.0× | 1e-12 |
| ChAHP complex assembly | 9 | 39.5× | 1e-11 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| nucleosome assembly | 14 | 33.9× | 1e-15 |
| heterochromatin formation | 7 | 30.8× | 6e-07 |
| DNA repair | 7 | 7.7× | 3e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
162 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 147 |
| Likely benign | 13 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
5183 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:97146816:T:C | donor_gain | 1.0000 |
| 6:97146840:T:C | donor_gain | 1.0000 |
| 6:97150017:CTGC:C | acceptor_gain | 1.0000 |
| 6:97151868:C:CC | acceptor_gain | 1.0000 |
| 6:97169387:T:C | donor_gain | 1.0000 |
| 6:97173140:T:TA | donor_gain | 1.0000 |
| 6:97173219:CAGC:C | acceptor_gain | 1.0000 |
| 6:97173222:CCT:C | acceptor_loss | 1.0000 |
| 6:97173223:C:CC | acceptor_gain | 1.0000 |
| 6:97173224:T:A | acceptor_loss | 1.0000 |
| 6:97178586:C:CC | acceptor_gain | 1.0000 |
| 6:97179402:A:AC | donor_gain | 1.0000 |
| 6:97179403:C:CC | donor_gain | 1.0000 |
| 6:97179407:CCAA:C | donor_gain | 1.0000 |
| 6:97179514:T:C | acceptor_gain | 1.0000 |
| 6:97179560:C:CC | acceptor_gain | 1.0000 |
| 6:97186686:TACTC:T | acceptor_gain | 1.0000 |
| 6:97186688:CTC:C | acceptor_gain | 1.0000 |
| 6:97186689:TCCTA:T | acceptor_loss | 1.0000 |
| 6:97186691:C:CC | acceptor_gain | 1.0000 |
| 6:97186692:T:C | acceptor_loss | 1.0000 |
| 6:97187395:C:CT | acceptor_gain | 1.0000 |
| 6:97187396:A:T | acceptor_gain | 1.0000 |
| 6:97229400:TATT:T | acceptor_gain | 1.0000 |
| 6:97229402:TT:T | acceptor_gain | 1.0000 |
| 6:97229404:C:CC | acceptor_gain | 1.0000 |
| 6:97231428:T:A | donor_gain | 1.0000 |
| 6:97246623:CATA:C | donor_loss | 1.0000 |
| 6:97246624:ATAC:A | donor_loss | 1.0000 |
| 6:97246626:ACCTG:A | donor_loss | 1.0000 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000003949 (6:97226465 G>A), RS1000004668 (6:97195101 T>G), RS1000005920 (6:97192788 T>A,C,G), RS1000054910 (6:97148872 G>A,T), RS1000104896 (6:97276357 A>G), RS1000106732 (6:97148555 T>C), RS1000110006 (6:97190850 G>A), RS1000112245 (6:97283080 G>A,C), RS1000135885 (6:97177455 T>C), RS1000146516 (6:97198501 T>C,G), RS1000153795 (6:97228145 T>A,G), RS1000189001 (6:97270971 A>C,T), RS1000213893 (6:97168462 C>T), RS1000221591 (6:97186261 G>A), RS1000226137 (6:97226771 G>A,C,T)
Disease associations
OMIM: gene MIM:615614 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
35 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001834_1 | Oleic acid (18:1n-9) levels | 3.000000e-07 |
| GCST002072_1 | Multiple sclerosis (OCB status) | 9.000000e-07 |
| GCST002783_309 | Body mass index | 5.000000e-06 |
| GCST002783_614 | Body mass index | 7.000000e-06 |
| GCST003263_54 | Post bronchodilator FEV1 in COPD | 4.000000e-06 |
| GCST003263_58 | Post bronchodilator FEV1 in COPD | 2.000000e-06 |
| GCST003263_59 | Post bronchodilator FEV1 in COPD | 4.000000e-06 |
| GCST003263_60 | Post bronchodilator FEV1 in COPD | 4.000000e-06 |
| GCST003263_61 | Post bronchodilator FEV1 in COPD | 4.000000e-06 |
| GCST003263_62 | Post bronchodilator FEV1 in COPD | 4.000000e-06 |
| GCST003265_261 | Post bronchodilator FEV1/FVC ratio in COPD | 1.000000e-06 |
| GCST003265_262 | Post bronchodilator FEV1/FVC ratio in COPD | 2.000000e-06 |
| GCST003265_263 | Post bronchodilator FEV1/FVC ratio in COPD | 2.000000e-06 |
| GCST003265_265 | Post bronchodilator FEV1/FVC ratio in COPD | 2.000000e-06 |
| GCST003265_266 | Post bronchodilator FEV1/FVC ratio in COPD | 2.000000e-06 |
| GCST003265_267 | Post bronchodilator FEV1/FVC ratio in COPD | 2.000000e-06 |
| GCST003265_268 | Post bronchodilator FEV1/FVC ratio in COPD | 2.000000e-06 |
| GCST003855_10 | Gut microbiota (bacterial taxa) | 2.000000e-08 |
| GCST003855_11 | Gut microbiota (bacterial taxa) | 2.000000e-08 |
| GCST003855_12 | Gut microbiota (bacterial taxa) | 2.000000e-08 |
| GCST003855_13 | Gut microbiota (bacterial taxa) | 4.000000e-08 |
| GCST003855_14 | Gut microbiota (bacterial taxa) | 4.000000e-08 |
| GCST003992_39 | Photic sneeze reflex | 1.000000e-17 |
| GCST004557_188 | Body mass index | 9.000000e-06 |
| GCST004557_57 | Body mass index | 3.000000e-08 |
| GCST004558_241 | Body mass index (joint analysis main effects and physical activity interaction) | 8.000000e-08 |
| GCST004559_169 | Body mass index in physically active individuals | 2.000000e-07 |
| GCST005830_56 | Hand grip strength | 1.000000e-08 |
| GCST007326_77 | Number of sexual partners | 4.000000e-08 |
| GCST007329_28 | Automobile speeding propensity | 3.000000e-08 |
EFO canonical traits (10, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004340 | body mass index |
| EFO:0004314 | forced expiratory volume |
| EFO:0004713 | FEV/FVC ratio |
| EFO:0007874 | gut microbiome measurement |
| EFO:0007887 | autosomal dominant compelling helio-ophthalmic outburst syndrome |
| EFO:0008002 | physical activity measurement |
| EFO:0006941 | grip strength measurement |
| EFO:0008579 | risk-taking behaviour |
| EFO:0008328 | chronotype measurement |
| EFO:0009863 | anxiety measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
27 total (human), top 27 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | decreases expression, increases expression, affects methylation | 4 |
| bisphenol A | decreases expression | 2 |
| Tobacco Smoke Pollution | decreases expression | 2 |
| Aflatoxin B1 | increases expression, increases methylation | 2 |
| aristolochic acid I | decreases expression | 1 |
| afuresertib | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| propionaldehyde | decreases expression | 1 |
| 2,2’-methylenebis(4-methyl-6-tert-butylphenol) | affects expression, affects response to substance | 1 |
| 2-butenal | decreases expression | 1 |
| beta-lapachone | increases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| aflatoxin B2 | decreases methylation | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| abrine | decreases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| Dasatinib | decreases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Calcitriol | decreases expression, affects cotreatment | 1 |
| Dichlorodiphenyl Dichloroethylene | increases expression | 1 |
| Melphalan | decreases expression | 1 |
| Testosterone | affects cotreatment, decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | increases expression | 1 |
| Aflatoxin M1 | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.